Find Reports

Select Report Type

Reimbursement Review

Displaying 551 - 575 of 1258

Please scroll or swipe to the right to view the full content.

Brand Name	Generic Name	Files	Therapeutic Area	Recommendation Type	Status	Submission Date	Recommendation Date Sort ascending	Project Number
Otezla	Apremilast	cdr_SR0478_Otezla_Resub.pdf SR0478_complete_Otezla-Oct-28-16.pdf SR0478_Otezla_PI_Submissions.pdf SR0478_Otezla_CL_Report_e.pdf SR0478_Otezla_PE_Report_e.pdf	Psoriasis, moderate to severe plaque	Reimburse with clinical criteria and/or conditions	Complete	Mar 3, 2016	Oct 26, 2016	SR0478-000
Brenzys	Etanercept	cdr_SE0485_TBC.pdf SE0485_complete_Brenzys-Oct-27-16.pdf se0485_brenzys_pi.pdf se0485_brenzys_seb_report.pdf	Rheumatoid arthritis, Ankylosing spondylitis	Reimburse with clinical criteria and/or conditions	Complete	Apr 20, 2016	Oct 25, 2016	SE0485-000
Inflectra (Subsequent Entry Biologic)	Infliximab	cdr_SE0483_Inflectra.pdf SE0483_IBD_Inflectra-Oct-28-16.pdf SE0483_Inflectra_PI_Submission_Consolidated.pdf SE0483_Inflectra_SEB_Report.pdf	Crohn’s disease and Ulcerative Colitis	Reimburse with clinical criteria and/or conditions	Complete	Apr 12, 2016	Oct 25, 2016	SE0483-000
Synjardy	Empagliflozin and metformin	Recommendation and Reasons: Updated Submission Status Report Recommendation and Reasons: Original Patient Group Input Submissions Clinical Report Pharmacoeconomic Report	Diabetes mellitus (Type 2)	Reimburse with clinical criteria and/or conditions	Complete	Apr 29, 2016	Oct 25, 2016	SR0489-000
Taltz	Ixekizumab	TS0001-PsO-Updated-Streamlined-Rec.pdf cdr_SR0481_TBC.pdf SR0481_complete_Taltz-oct-27-16.pdf SR0481_Taltz_PI_Submissions.pdf SR0481_Taltz_CL_Report_e.pdf SR0481_Taltz_PE_Report_e.pdf	Psoriasis, moderate to severe plaque	Reimburse with clinical criteria and/or conditions	Complete	Mar 23, 2016	Oct 25, 2016	SR0481-000
Lynparza	Olaparib	pcodr_provfund_olaparib_lynparza_oc.pdf pcodr_olaparib_lynparza_oc_fn_rec.pdf pcodr_olaparib_lynparza_oc_fn_cgr.pdf pcodr_olaparib_lynparza_oc_fn_egr.pdf pcodr_olaparib_lynparza_oc_in_rec.pdf pcodr_olaparib_lynparza_oc_pagfdk.pdf pcodr_olaparib_lynparza_oc_fdk_azc.pdf pcodr_olaparib_lynparza_oc_ptfdk.pdf pcodr_olaparib_lynparza_oc_coi_occ.pdf pcodr_olaparib_lynparza_oc_fdk_clinician.pdf pcodr_olaparib_lynparza_oc_coi_clinician.pdf	Ovarian Cancer	Do not reimburse	Complete	Apr 1, 2016	Sep 29, 2016	PC0081-000
Zydelig	Idelalisib	pcodr-provfund_idelalisib-zydelig-fl.pdf pcodr_idelalisib_zydelig_fl_fn_rec.pdf pcodr_idelalisib_zydelig_fl_fn_cgr.pdf pcodr_idelalisib_zydelig_fl_fn_egr.pdf pcodr_idelalisib_zydelig_fl_in_rec.pdf pcodr_idelalisib_zydelig_fl_pagfdk.pdf pcodr_idelalisib_zydelig_fl_fdk_gilead.pdf pcodr_idelalisib_zydelig_fl_ptfdk_lc.pdf pcodr_idelalisib_zydelig_fl_coi_lc.pdf	Follicular Lymphoma	Do not reimburse	Complete	Apr 12, 2016	Sep 29, 2016	PC0075-000
Lenvima	Lenvatinib	pcodr-provfund_lenvatinib-lenvima-dtc.pdf pcodr_lenvatinib_lenvima_dtc_fn_rec.pdf pcodr_lenvatinib_lenvima_dtc_fn_cgr.pdf pcodr_lenvatinib_lenvima_dtc_fn_egr.pdf pcodr_lenvatinib_lenvima_dtc_in_rec.pdf pcodr_lenvatinib_lenvima_dtc_pagfdk.pdf pcodr_lenvatinib_lenvima_dtc_fdk_eisailtd.pdf pcodr_lenvatinib_lenvima_dtc_coi_tcc.pdf pcodr_lenvatinib_lenvima_dtc_coi_clinicians.pdf	Differentiated Thyroid Cancer	Reimburse with clinical criteria and/or conditions	Complete	Apr 18, 2016	Sep 20, 2016	PC0080-000
Opdivo	Nivolumab	pcodr-provfund_nivolumab-opdivo-mrcc.pdf pcodr_nivolumab_opdivo_mrcc_fn_rec.pdf pcodr_nivolumab_opdivo_mrcc_fn_cgr.pdf pcodr_nivolumab_opdivo_mrcc_fn_egr.pdf pcodr_nivolumab_opdivo_mrcc_in_rec.pdf pcodr_nivolumab_opdivo_mrcc_pagfdk.pdf pcodr_nivolumab_opdivo_mrcc_fdk_bms.pdf pcodr_nivolumab_opdivo_mrcc_ptfdk_kcc.pdf pcodr_nivolumab_opdivo_mrcc_coi_kcc.pdf	Metastatic Renal Cell Carcinoma	Reimburse with clinical criteria and/or conditions	Complete	Feb 24, 2016	Sep 1, 2016	PC0074-000
Brilinta	ticagrelor	cdr_SR0474_Brilinta.pdf SR0474_complete_Brilinta-Aug-29-16.pdf SR0474_Brilinta_CL_Report.pdf SR0474_Brilinta_PE_Report.pdf SR0474_Brilinta_PI_Submissions.pdf	Prevention of atherothrombotic events with history of myocardial infarction	Reimburse with clinical criteria and/or conditions	Complete	Feb 18, 2016	Aug 25, 2016	SR0474-000
Invokamet	Canagliflozin and metformin hydrochloride	cdr_SR0480_TBC.pdf SR0480_complete_Invokamet-Aug-29-16.pdf SR0480_Invokamet_Combination_Product_Subsmission_Report.pdf SR0480_Invokamet_PI_Submissions.pdf	diabetes mellitus, type 2	Reimburse with clinical criteria and/or conditions	Complete	Mar 3, 2016	Aug 25, 2016	SR0480-000
Descovy	Emtricitabine /tenofovir alafenamide	cdr_SR0470_TBC.pdf SR0470_complete_Descovy-Aug-26-16.pdf SR0470_Descovy_CL_Report.pdf SR0470_Descovy_PE_Report.pdf SR0470_Descovy_PI_Submissions.pdf	HIV-1 infection	Reimburse with clinical criteria and/or conditions	Complete	Jan 29, 2016	Aug 24, 2016	SR0470-000
Egrifta	Tesamorelin	cdr_SR0477_Egrifta.pdf SR0477_complete_Egrifta_Aug-26-16.pdf SR0477_Egrifta_CL_Report.pdf SR0477_Egrifta_PE_Report.pdf SR0477_Egrifta_PI_Submissions.pdf	Lipodystrophy, HIV-infected patients	Do not reimburse	Complete	Mar 2, 2016	Aug 24, 2016	SR0477-000
Truvada	Emtricitabine/tenofovir disoproxil fumarate	cdr_SR0479_Truvada.pdf SR0479_complete_Truvada_Aug-26-16.pdf SR0479_Truvada_CL_Report.pdf SR0479_Truvada_PE_Report.pdf SR0479_Truvada_PI_Submissions.pdf	HIV-1 infection, pre-exposure prophylaxis	Reimburse with clinical criteria and/or conditions	Complete	Mar 3, 2016	Aug 24, 2016	SR0479-000
Cosentyx	Secukinumab	cdr_SR0475_Cosentyx_AS.pdf SR0475_complete_Cosentyx_AS_Aug-25-16.pdf SR0475_CosentyxAS_CL_Report.pdf SR0475_CosentyxAS_PE_Report.pdf SR0475_CosentyxAS_PI_Submissions.pdf	ankylosing spondylitis	Reimburse with clinical criteria and/or conditions	Complete	Feb 19, 2016	Aug 23, 2016	SR0475-000
Cosentyx	Secukinumab	cdr_SR0476_Cosentyx_PsA.pdf SR0476_complete_Cosentyx_PsA_Aug-25-16.pdf SR0476_CosentyxPsA_CL_Report.pdf SR0476_CosentyxPsA_PE_Report.pdf SR0476_CosentyxPsA_PI_Submissions.pdf	Arthritis, psoriatic	Reimburse with clinical criteria and/or conditions	Complete	Feb 19, 2016	Aug 23, 2016	SR0476-000
Yondelis	Trabectedin	pcodr_provfund_trabectedin_yondelis_lipo-leio.pdf pcodr_trabectedin_yondelis_lile_scarcoma_fn_rec.pdf pcodr_trabectedin_yondelis_lile_scarcoma_fn_cgr.pdf pcodr_trabectedin_yondelis_lile_scarcoma_fn_egr.pdf pcodr_trabectedin_yondelis_lile_scarcoma_in_rec.pdf pcodr_trabectedin_yondelis_lile_scarcoma_pagfdk.pdf pcodr_trabectedin_yondelis_lile_scarcoma_fdk_janssen.pdf pcodr_trabectedin_yondelis_lile_scarcoma_coi_scfc.pdf	Metastatic Liposarcoma or Leiomyosarcoma	Do not reimburse	Complete	Dec 22, 2015	Aug 5, 2016	PC0071-000
Revestive	Teduglutide	cdr_SR0459_Revestive.pdf SR0459_Revestive_complete_Jul-29_16.pdf SR0459_Revestive_CL_Report.pdf SR0459_Revestive_PE_Report.pdf SR0459_Revestive_PI_Submissions.pdf	Short bowel syndrome	Reimburse with clinical criteria and/or conditions	Complete	Nov 26, 2015	Jul 27, 2016	SR0459-000
Eylea	Aflibercept	SR0460 Eylea.pdf SR0460_Eylea BRVO_complete_Jul-29_16.pdf SR0460_Eylea_BRVO_CL_Report.pdf SR0460_Eylea_BRVO_PE_Report.pdf	Macular edema, branch retinal vein occlusion	Reimburse with clinical criteria and/or conditions	Complete	Dec 14, 2015	Jul 27, 2016	SR0460-000
XigDuo	dapagliflozin/metformin hydrochloride	Recommendation and Reasons: Updated Submission Status Report Recommendation and Reasons: Original Patient Group Input Submissions Fixed‐Dose Combination Report Summary Report	Diabetes Mellitus, Type 2	Reimburse with clinical criteria and/or conditions	Complete	Jan 7, 2016	Jul 20, 2016	SR0468-000
Praluent	Alirocumab	cdr_SR0469_Praluent.pdf SR0469_complete_Praluent_Jul-20-16.pdf SR0469_Praluent_CL_Report.pdf SR0469_Praluent_PE_Report.pdf SR0469_Praluent_PI_Submissions.pdf	Primary hypercholesterolemia (non-familial and heterozygous familial), mixed dyslipidemia	Reimburse with clinical criteria and/or conditions	Complete	Jan 12, 2016	Jul 20, 2016	SR0469-000
Sunvepra	Asunaprevir	SR0418 Sunvepra.pdf SR0418_complete_Sunvepra_Jul-20_16.pdf SR0418_Sunvepra_CL_Report.pdf SR0418_Sunvepra_PE_Report.pdf SR0418_Sunvepra_PI_Submissions.pdf	Hepatitis C, chronic	Reimburse with clinical criteria and/or conditions	Complete	Feb 13, 2015	Jul 20, 2016	SR0418-000
Imbruvica	Ibrutinib	pcodr-provfund_ibrutinib_imbruvica_mcl.pdf pcodr_ibrutinib_imbruvica_mcl_fn_rec.pdf pcodr_ibrutinib_imbruvica_mcl_fn_cgr.pdf pcodr_ibrutinib_imbruvica_mcl_fn_egr.pdf pcodr_ibrutinib_imbruvica_mcl_in_rec.pdf pcodr_ibrutinib_imbruvica_mcl_pagfdk.pdf pcodr_ibrutinib_imbruvica_mcl_fdk_janssen.pdf pcodr_ibrutinib_imbruvica_mcl_ptfdk_lfc.pdf pcodr_ibrutinib_imbruvica_mcl_ptfdk_llsc-ccsn.pdf pcodr_ibrutinib_imbruvica_mcl_coi_lfc.pdf pcodr_ibrutinib_imbruvica_mcl_coi_llsc-ccsn.pdf	Mantle Cell Lymphoma (relapsed/refractory)	Reimburse with clinical criteria and/or conditions	Complete	Jan 29, 2016	Jul 19, 2016	PC0073-000
Cotellic	Cobimetinib	pcodr_provfund_cobimetinib_cotellic_metmela.pdf pcodr_cobimetinib_cotellic_metmela_fn_rec.pdf pcodr_cobimetinib_cotellic_metmela_fn_cgr.pdf pcodr_cobimetinib_cotellic_metmela_fn_egr.pdf pcodr_cobimetinib_cotellic_metmela_in_rec.pdf pcodr_cobimetinib_cotellic_metmela_pagfdk.pdf pcodr_cobimetinib_cotellic_metmela_fdk_roche.pdf pcodr_cobimetinib_cotellic_metmela_ptgrpfdk.pdf pcodr_cobimetinib_cotellic_metmela_coi_mnc.pdf pcodr_cobimetinib_cotellic_metmela_coi_sysf.pdf	Metastatic melanoma	Reimburse with clinical criteria and/or conditions	Complete	Dec 11, 2015	Jun 30, 2016	PC0070-000
Kyprolis (with lenalidomide)	Carfilzomib (with lenalidomide)	pcodr_profund_10067carfilzomib_kyprolis_lenalidomide_mm.pdf pcodr_carfilzomib_kyprolis_mm_fn_rec.pdf pcodr_carfilzomib_kyprolis_mm_fn_cgr.pdf pcodr_carfilzomib_kyprolis_mm_fn_egr.pdf pcodr_carfilzomib_kyprolis_mm_in_rec.pdf pcodr_carfilzomib_kyprolis_mm_pagfdk.pdf pcodr_carfilzomib_kyprolis_mm_fdk_amgen.pdf pcodr_carfilzomib_kyprolis_mm_coi_mc.pdf	Multiple Myeloma	Reimburse with clinical criteria and/or conditions	Complete	Dec 11, 2015	Jun 21, 2016	PC0067-000

Health Technology Review

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 551 - 575 of 589

Please scroll or swipe to the right to view the full content.

Title	Files	Last Updated Sort ascending	Project Sub Line	Status	Project Number
Collaboration in Health Technology Assessment in Canada		Sep 6, 2019	Environmental Scan	Completed	ES0329-000
Axicabtagene Ciloleucel for Adults With Relapsed or Refractory Large B-cell Lymphoma		Aug 15, 2019	Optimal Use	Completed	CT0002-000
Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Recommendations		Aug 15, 2019		Completed	CT0002-000
Buprenorphine-Naloxone Tablet Versus Methadone for the Treatment of Patients with Opioid Use Disorder: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines	RC1150 Suboxone vs.pdf	Jul 31, 2019	Summary with Critical Appraisal	Completed	RC1150-000
Appropriate Pharmacotherapy for Inflammatory Bowel Disease	ho0003-he0018-ibd-ou360.pdf	Jun 6, 2019	Technology Review	Completed	HO0003-000 - HE0018-000
Appropriate Pharmacotherapy for Inflammatory Bowel Disease		Jun 5, 2019	Technology Review	Completed	HO0003-000 - HE0018-000
Criteria for conducting Environmental Assessments in CADTH HTAs		Jun 5, 2019		In Progress	MG0017-000
Buprenorphine for Opioid Use Disorders during Pregnancy: A Review of Comparative Clinical Effectiveness, Safety, Cost-Effectiveness, and Guidelines	RC1111 Buprenorphine for Opioid Use Disorder During Pregnancy Final.pdf	May 9, 2019	Summary with Critical Appraisal	Completed	RC1111-000
Rural Breast Cancer Surgery Programs: A Rapid Qualitative Review	Rural Breast Cancer Surgery Programs: A Rapid Qualitative Review	May 3, 2019	Rapid Review	Completed	RC1104-000
Prescription Drug Monitoring Programs: A Rapid Qualitative Review	Prescription Drug Monitoring Programs: A Rapid Qualitative Review	Apr 30, 2019	Rapid Review	Completed	RC1097-000
Buprenorphine for Opioid Use Disorder: A Review of Comparative Clinical Effectiveness, Safety, Cost-Effectiveness, and Guidelines	RC1092 Buprenorphine for OUD Final.pdf	Apr 24, 2019	Summary with Critical Appraisal	Completed	RC1092-000
Gene Expression Profiling Tests for Breast Cancer: A Rapid Qualitative Review	Gene Expression Profiling Tests for Breast Cancer: A Rapid Qualitative Review	Apr 18, 2019	Summary with Critical Appraisal	Completed	RC1099-000
Health Technology Reassessment: An Overview of Canadian and International Processes		Mar 22, 2019			ES0334-000
Environmental Scan on Health Technology Reassessment Processes		Mar 22, 2019			ES0334-000
Reimbursement Status of Newer Drugs for the Treatment of Type 2 Diabetes		Feb 27, 2019	Environmental Scan	Completed	ES0337-000
Reimbursement of Newer Drugs for Type 2 Diabetes in Canada: An Environmental Scan		Feb 26, 2019	Environmental Scan	Completed	ES0337-000
Tisagenlecleucel (Kymriah) for Pediatric Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma	media:document:d00ebe66-c3ca-4630-a5c9-9db0789e0f05 media:document:d878e503-9902-4b9a-b462-1c08b76ea345 media:document:db2f1690-ae45-427b-926d-e7e0b29a66b6	Jan 15, 2019	Optimal Use	Completed	OP0538-000 / CT0001
Tisagenlecleucel for Acute Lymphoblastic Leukemia and Diffuse Large B-cell Lymphoma: Recommendations		Jan 15, 2019	Optimal Use	Completed	OP0538-000 / CT0001
Detection and Diagnosis of Sepsis in Rural and Remote Areas: An Environmental Scan		Jan 9, 2019	Environmental Scan	Completed	ES0327-000
Engaging with History Taking for Adverse Childhood Experiences in Care: A Rapid Qualitative Review	Engaging with History Taking for Adverse Childhood Experiences in Care: A Rapid…	Nov 19, 2018	Rapid Review	Completed	RC1045-000
Drugs for Rare Diseases: A Review of National and International Health Technology Assessment Agencies and Public Payers’ Decision-Making Processes		Jun 26, 2018	Environmental Scan	Completed	ES0326-000
Recommendations Framework for Drugs for Rare Diseases: A Review of National and International Health Technology Assessment Agencies and Public Payers’ Decision-Making Processes		Jun 22, 2018			ES0326-000
Drugs for the Management of Rheumatoid Arthritis		Apr 25, 2018	Health Technology Assessment	Completed	HT0010-000
Use of Real-World Evidence in Single-Drug Assessments Environmental Scan		Apr 18, 2018	Environmental Scan	Completed	ES0323-000
Gene Therapy: International Regulatory and Health Technology Assessment (HTA) Activities and Reimbursement Status		Mar 28, 2018	Environmental Scan	Completed	ES0325-000

Horizon Scan

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 101 - 111 of 111

Projects in Progress

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 26 - 40 of 40

View All Reports

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 551 - 575 of 2093

Please scroll or swipe to the right to view the full content.

Title	Files	Last Updated Sort ascending	Project Line	Project Sub Line	Status	Project Number
Xylazine Test Strips for Drug Checking	Xylazine Test Strips for Drug Checking	Jul 17, 2023	Horizon Scan	Health Technology Update	Completed	EN0049-000
Electrostimulation Devices for Wounds	Electrostimulation Devices for Wounds	Jul 17, 2023	Health Technology Review	Rapid Review	Completed	RC1489-000
Point-of-Care HIV and Syphilis Screening	Point-of-Care HIV and Syphilis Screening	Jul 13, 2023	Health Technology Review	Rapid Review	Completed	RC1490-000
caplacizumab	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Jul 13, 2023	Reimbursement Review		Complete	SR0736-000
brexucabtagene autoleucel	Recommendation and Reasons Clinical, Pharmacoeconomic and Ethics combined Report Stakeholder feedback on Draft Recommendation	Jul 11, 2023	Reimbursement Review		Complete	PG0304-000
nivolumab	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Jul 11, 2023	Reimbursement Review		Complete	PC0303-000
Platelet-Rich Plasma Injections for Chronic Tendinopathies in the Lower Extremities	Platelet-Rich Plasma Injections for Chronic Tendinopathies in the Lower Extremities	Jul 10, 2023	Health Technology Review	Rapid Review	Completed	RC1486-000
Riluzole for Amyotrophic Lateral Sclerosis Treatment	Riluzole for Amyotrophic Lateral Sclerosis Treatment	Jul 7, 2023	Health Technology Review	Rapid Review	Completed	RC1487-000
Treatment of Adult Patients With Immune Thrombocytopenia After Failure of First-Line Therapies	Treatment of Adult Patients With Immune Thrombocytopenia After Failure of First…Project Protocol	Jul 6, 2023	Health Technology Review	Health Technology Assessment	Completed	HT0035-000
Hearing Aids and Dementia	Hearing Aids and Dementia	Jul 6, 2023	Horizon Scan	Emerging Health Technologies	Completed	EH0120-000
Rapid HIV Self-Testing	Rapid HIV Self-Testing	Jun 30, 2023	Horizon Scan	Emerging Health Technologies	Completed	EH0118-000
Alternative Therapies to Immunoglobulin for Idiopathic Inflammatory Myopathies	Alternative Therapies to Immunoglobulin for Idiopathic Inflammatory Myopathies	Jun 29, 2023	Health Technology Review	Rapid Review	Completed	RC1484-000
Adult B-Cell Precursor Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative and Positive	Final Report	Jun 28, 2023	Reimbursement Review	Provisional Funding Algorithm	Complete	PH0030-000
Antimicrobial or Antiseptic Cleansers for Wounds	Antimicrobial or Antiseptic Cleansers for Wounds	Jun 28, 2023	Health Technology Review	Rapid Review	Completed	RC1488-000
mavacamten	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Jun 23, 2023	Reimbursement Review		Complete	SR0755-000
CADTH Pharmaceutical Reviews Update — Issue 39		Jun 22, 2023	Reimbursement Review	Pharmaceutical Review Update
Triple Negative Breast Cancer	Final Report	Jun 14, 2023	Reimbursement Review	Provisional Funding Algorithm	Complete	PH0024-000
Deep Brain Stimulation Surgery Programs in Canada	Deep Brain Stimulation Surgery Programs in Canada	Jun 13, 2023	Health Technology Review	Technology Review	Completed	HC0065-000
Hybrid Operating Rooms Suites	Hybrid Operating Rooms Suites	Jun 9, 2023	Horizon Scan	Emerging Health Technologies	Completed	EH0121-000
axicabtagene ciloleucel	Recommendation and Reasons Clinical, Pharmacoeconomic and Ethics combined Report Stakeholder feedback on Draft Recommendation	Jun 9, 2023	Reimbursement Review		Complete	PG0293-000
CADTH Pharmaceutical Reviews Update — Issue 38		Jun 8, 2023	Reimbursement Review	Pharmaceutical Review Update
ravulizumab	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Jun 8, 2023	Reimbursement Review		Complete	SR0740-000
An Overview of Pharmacogenomic Testing for Psychiatric Disorders	An Overview of Pharmacogenomic Testing for Psychiatric Disorders	Jun 6, 2023	Horizon Scan	Emerging Health Technologies	Completed	EH0115-000
Non-Small Cell Lung Cancer (NSCLC) with Activating Epidermal Growth Factor Receptor (EGFR) Mutations	Final Report	Jun 1, 2023	Reimbursement Review	Provisional Funding Algorithm	Complete	PH0028-000
RET fusion-positive non-small cell lung cancer	Final Report	Jun 1, 2023	Reimbursement Review	Provisional Funding Algorithm	Complete	PH0026-000